Literature DB >> 11134139

Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves' disease and thyroid autonomy and in thyroid-derived cell populations.

C Simchen1, I Lehmann, D Sittig, M Steinert, G Aust.   

Abstract

Thyroid glands affected by Graves' disease (GD) show striking lymphocytic infiltration, mainly by CD45RO(+) T cells. The mechanisms by which the various lymphocytic subsets are recruited and maintained in the thyroid are unknown. RANTES (regulated on activation, normal T cells expressed and secreted) in interaction with its receptors (CCR1, CCR3, CCR4 and CCR5) may be one of the favorite chemokines involved in the cell trafficking and maintenance. RANTES messenger RNA (mRNA) was quantified in the thyroid tissue of 16 patients with GD and 7 patients with thyroid autonomy (TA), using competitive RT-PCR. We found a clear correlation between the RANTES mRNA level and 1) the degree of T-cell infiltration (r = 0.68), and 2) the level of serum antibodies to thyroid peroxidase (r = 0.76) in GD but not in TA patients. There was no difference between the autonomous nodules and the quiescent surrounding tissue in TA patients. To define the cellular source of RANTES mRNA and protein, we examined various thyroid-derived cells. Lymphocytes showed a markedly higher basal RANTES mRNA and protein level (mean +/- SEM; pg/mL, n = 3; 140 +/- 30) than thyrocytes (12 +/- 5) and fibroblasts (9 +/- 2). Lymphocyte stimulation with PMA enhanced RANTES secretion significantly (4490 +/- 200). Fibroblasts responded to stimulation with interleukin 1 (530 +/- 220) and tumor necrosis factor alpha (2780 +/- 1790), whereas thyrocytes did not. However, some thyroid carcinoma cell lines showed very high basal and stimulated RANTES expression. Lymphocytes expressed the mRNA of all chemokine receptors that bind RANTES. The number of CCR3(+) and CCR5(+) T cells was significantly higher in thyroid-derived leukocytes than in those in the peripheral blood stream. We conclude that RANTES expression, mainly by lymphocytes, is perhaps involved in the maintenance of lymphocytic infiltration and, therefore, in the autoimmune responses in GD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134139     DOI: 10.1210/jcem.85.12.7082

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

2.  Intersection of Chemokine and TSH Receptor Pathways in Human Fibrocytes: Emergence of CXCL-12/CXCR4 Cross Talk Potentially Relevant to Thyroid-Associated Ophthalmopathy.

Authors:  Roshini Fernando; Stephen J Atkins; Terry J Smith
Journal:  Endocrinology       Date:  2016-07-29       Impact factor: 4.736

Review 3.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  One-tube-PCR technique for CCL2, CCL3, CCL4 and CCL5 applied to fine needle aspiration biopsies shows different profiles in autoimmune and non-autoimmune thyroid disorders.

Authors:  X Ferrer-Francesch; P Caro; L Alcalde; M P Armengol; Y Ashhab; A Lucas-Martín; E M Martínez-Cáceres; M Juan; R Pujol-Borrell
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

5.  Graves' disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes.

Authors:  G Aust; D Sittig; M Steinert; P Lamesch; T Lohmann
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 6.  Pathogenesis of Graves' orbitopathy: a 2010 update.

Authors:  T J Smith
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

7.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

8.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.

Authors:  Paola Romagnani; Mario Rotondi; Elena Lazzeri; Laura Lasagni; Michela Francalanci; Andrea Buonamano; Stefano Milani; Paolo Vitti; Luca Chiovato; Massimo Tonacchera; Antonio Bellastella; Mario Serio
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  CXCR3, CCR5, and CRTH2 Chemokine Receptor Expression in Lymphocytes Infiltrating Thyroid Nodules with Coincident Hashimoto's Thyroiditis Obtained by Fine Needle Aspiration Biopsy.

Authors:  Jan Jiskra; Marie Antošová; Jan Krátký; Hana Vítková; Zdeňka Límanová; Helena Marečková; Eliška Potluková
Journal:  J Immunol Res       Date:  2016-10-31       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.